Cytokinetics, Inc. (CYTK)

[Transparency]

"During the first quarter, Cytokinetics convened meetings with each of FDA and EMA to review results from BENEFIT-ALS and to discuss plans to advance tirasemtiv to the next stage of clinical development. Based on feedback from those meetings, Cytokinetics is preparing to initiate a large, international Phase III clinical trial of tirasemtiv in patients with ALS." stated Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "In addition, we are pleased that COSMIC-HF recently completed patient enrollment. We are readying for the availability of results from this clinical trial which are expected later this year and are preparing for the potential progression of omecamtiv mecarbil to Phase III in collaboration with Amgen."